Uridin-2',3',5'-triacetat Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Uridine
triacetate is an orally available pro-drug of uridine approved by
the FDA for the treatment of the rare autosomal recessive
disorder called hereditary orotic aciduria. The drug was also
approved for treating overdose of two chemotherapies
(fluorouracil and capecitabine). Uridine triacetate was
developed by Wellstat Therapeutics and licensed to BTG.
Chemische Eigenschaften
White or almost white crystalline powder
Verwenden
2’,3’,5’-Triacetyluridine is used in the treatment of Alzheimer’s disease in mice and provide neuroprotective effects. Shown to also decrease depressive symptoms and increases in brain pH bipolar patients.
Definition
ChEBI: Uridine triacetate is an acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity. It has a role as a prodrug, a neuroprotective agent and an orphan drug. It is a member of uridines and an acetate ester.
Einzelnachweise
[1] E.D. Gudio, M.L. Ferreira, L.E. Iglesias . “A rational approach to the regioselective deacetylation of 2′,3′,5′-tri-O-acetyluridine by Novozym 435 catalysed alcoholysis.” Biochimica et biophysica acta. Proteins and proteomics 1824 4 (2012): Pages 627-636.
[2] Osama M Ashour . “Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2′,3′,5′-tri-O-acetyluridine, a prodrug of uridine.” Biochemical pharmacology 60 3 (2000): Pages 427-431.
Uridin-2',3',5'-triacetat Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
